← feed

Is NCT03282513 results overdue?

Yes — results are overdue. Primary completion was 2018-03-31; the FDAAA-801 reporting deadline (2019-03-31) passed 2685 days ago and no results are posted on ClinicalTrials.gov.

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

NCT IDNCT03282513 ↗
SponsorAgios Pharmaceuticals, Inc. (INDUSTRY)
Public issuerAGIOS PHARMACEUTICALS, INC. — AGIO (CIK 0001439222) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-03-31 (ACTUAL)
Reporting deadline2019-03-31 (completion + 365d)
Days overdue2685
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 f7856a3f5ceac1af… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03282513. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →